Current acellular pertussis vaccines prevent disease but do not prevent nasal infection and transmission of Bordetella pertussis. However, immunology is helping to design new vaccines that induce sterilizing immunity.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Proc. Natl Acad. Sci. USA 111, 787–792 (2014).
Wilk, M. M. et al. Emerg. Microbes Infect. 8, 169–185 (2019).
da Silva Antunes, R. et al. J. Clin. Invest. 128, 3853–3865 (2018).
Allen, A. C. et al. Mucosal Immunol. 11, 1763–1776 (2018).
Solans, L. et al. Mucosal Immunol. 11, 1753–1762 (2018).
The author is an inventor on a patent around a new pertussis vaccine and receives research funding from and consults for vaccine manufacturers.
About this article
Cite this article
Mills, K.H.G. How immunology can help reverse the pertussis vaccine failure. Nat Immunol 24, 1779–1780 (2023). https://doi.org/10.1038/s41590-023-01625-8